Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: Over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Tian, Yiming ^a   Huang, Zoufang ^a   Wang, Zhixiang ^a   Yin, Changxin ^a   Zhou, Lanlan ^a   Zhang, Lingxiu ^a   Huang, Kaikai ^a   Zhou, Hongsheng ^a   Jiang, Xuejie ^a   Li, Jinming ^a   Liao, Libin ^a   Yang, Mo ^a,b   Meng, Fanyi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANGIOPOIETIN 2; ANTHRACYCLINE; CYTARABINE; FISSION 1; GAMMA GLUTAMYLTRANSFERASE; METHOTREXATE; PROGRAMMED CELL DEATH 7 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANG2 GENE; ANIMAL CELL; APP GENE; ARTICLE; ATCAY GENE; CA6 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG MEGADOSE; FAM3A GENE; FEMALE; FIS1 GENE; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GGT5 GENE; HUMAN; KLRF1 GENE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PDCD7 GENE; PHARMACOGENETICS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CASE-CONTROL STUDIES; CYTOGENETIC ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOBLOTTING; LECTINS, C-TYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, NATURAL KILLER CELL; RECURRENCE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VESICULAR TRANSPORT PROTEINS; YOUNG ADULT;

EID: 84897424494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084150     Document Type: Article

References (38)

1. Damm F, Heuser M, Morgan M, Wagner K, Gorlich K, et al. (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117: 4561-4568.
2. Tang J, Meng FY, Ma W, Shi R (2006) Gene expression profile associated with prognosis in acute myeloid leukemia. Guo Ji Shu Xue Ji Xue Ye Xue Za Zhi 29: 297-301.
3. Hou HA, Chou WC, Lin LI, Tang JL, Tseng MH, et al. (2008) Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 32: 904-912.
4. Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, et al. (2005) Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 23: 1109-1117. (Pubitemid 46202266)
5. Schliemann C, Bieker R, Thoennissen N, Gerss J, Liersch R, et al. (2007) Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 21: 1901-1906. (Pubitemid 47299962)
6. Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, et al. (2006) Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 91: 1203-1211. (Pubitemid 44408430)
7. Jaffe ES, Harris NL, Stein H, Vardiman JW, Editors. (2001) World Health Organiazation Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France.
8. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
9. Jiang XJ, Huang KK, Yang M, Qiao L, Meng FY, et al. (2012) Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-kappaB pathways. Cancer Lett 326: 135-142.
10. Estey E (1996) Treatment of refractory AML. Leukemia 10: 932-936.
11. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, et al. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642-4649. (Pubitemid 46594039)
12. Juliusson G, Antunovic P, Derolf Å, Lehmann S, Möllgård L, et al. (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113: 4179-4187.
13. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, et al. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115: 453-474.
14. O'Donnell MR, Appelbaum FR, Baer MR, Byrd JC, Coutre SE, et al. (2005) the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology on Acute Myeloid Leukemia-v.2.2005.
15. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, et al. (2011) the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology on Acute Myeloid Leukemia-v.2.2011.
16. Will CL, Schneider C, Hossbach M, Urlaub H, Rauhut R, et al. (2004) The human 18S U11/U12 snRNP contains a set of novel proteins not found in the U2-dependent spliceosome. RNA 10: 929-941. (Pubitemid 38669766)
17. Benecke H, Luhrmann R, Will CL (2005) The U11/U12 snRNP 65K protein acts as a molecular bridge, binding the U12 snRNA and U11-59K protein. EMBO J 24: 3057-3069. (Pubitemid 41486342)
18. Turunen JJ, Will CL, Grote M, Luhrmann R, Frilander MJ (2008) The U11-48K protein contacts the 5′ splice site of U12-type introns and the U11-59K protein. Mol Cell Biol 28: 3548-3560. (Pubitemid 351657115)
19. Park EJ, Kim JH, Seong RH, Kim CG, Park SD, et al. (1999) Characterization of a novel mouse cDNA, ES18, involved in apoptotic cell death of T-cells. Nucleic Acids Res 27: 1524-1530. (Pubitemid 29206296)
20. Mai S, Klinkenberg M, Auburger G, Bereiter-Hahn J, Jendrach M (2010) Decreased expression of Drp1 and Fis1 mediates mitochondrial elongation in senescent cells and enhances resistance to oxidative stress through PINK1. J Cell Sci 123: 917-926.
21. Manczak M, Peizhong M, Calkins M, Cornea A, Arubala RP, et al. (2010) Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons Journal Of Alzheimer's Disease: JAD Vol. 20.
22. Rakovic A, Grunewald A, Kottwitz J, Bruggemann N, Pramstaller PP, et al. (2011) Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS One 6: e16746.
23. Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U, et al. (2011) Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Research Reviews 67: 103-118.
24. Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, et al. (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet 20: 1438-1455.
25. Wang B, Heath-Engel H, Zhang D, Nguyen N, Thomas DY, et al. (2008) BAP31 interacts with Sec61 translocons and promotes retrotranslocation of CFTRDeltaF508 via the derlin-1 complex. Cell 133: 1080-1092. (Pubitemid 351787744)
26. Rizzuto R, Marchi S, Bonora M, Aguiari P, Bononi A, et al. (2009) Ca(2+) transfer from the ER to mitochondria: when, how and why. Biochim Biophys Acta 1787: 1342-1351.
27. Iwasawa R, Mahul-Mellier AL, Datler C, Pazarentzos E, Grimm S (2011) Fis1 and Bap31 bridge the mitochondria-ER interface to establish a platform for apoptosis induction. EMBO J 30: 556-568.
28. Kaddour-Djebbar I, Choudhary V, Brooks C, Ghazaly T, Lakshmikanthan V, et al. (2010) Specific mitochondrial calcium overload induces mitochondrial fission in prostate cancer cells. Int J Oncol 36: 1437-1444.
29. Sastre-Serra J, Nadal-Serrano M, Pons DG, Roca P, Oliver J (2012) Mitochondrial dynamics is affected by 17beta-estradiol in the MCF-7 breast cancer cell line. Effects on fusion and fission related genes. Int J Biochem Cell Biol 44: 1901-1905.
30. Tang JM, Meng FY, Ma WL (2005) [Evolution of gene expression profile in 3 cases of acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 26: 653-655.
31. Wang W, Meng FY, Huang Z, Li L, Cai Y, et al. (2009) Expressions of APP,Fis1,PDCD7 and KLRF1 mRNA in acute myeloid leukemia. Nan Fang Yi Ke Da Xue Xue Bao 29: 2259-2264.
32. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60. (Pubitemid 27450643)
33. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, et al. (1997) Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100: 2072-2078. (Pubitemid 27459362)
34. Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99: 11205-11210. (Pubitemid 34920903)
35. Visconti RP, Richardson CD, Sato TN (2002) Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 99: 8219-8224. (Pubitemid 34651033)
36. Huang H, Zheng X, Tian Z, Sun R (2010) Peptide mimicry of AICL inhibits cytolysis of NK cells by blocking NKp80-AICL recognition. Immunol Invest 39: 587-597.
37. Vitale M, Falco M, Castriconi R, Parolini S, Zambello R, et al. (2001) Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol 31: 233-242.
38. Kuttruff S, Koch S, Kelp A, Pawelec G, Rammensee HG, et al. (2009) NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood 113: 358-369.